ClinicalTrials.gg
CompletedNCT02217566Updated Jan 13, 2020Results posted

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

A Phase 2 interventional study of Abiraterone acetate and Prednisone in Prostatic Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 5 sites in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
56th of 98
46 · median 56
Started
2014
with 9 others
Phase 2
59 of 98
9 open now
Registered
43rd of 98
by date
Lead sponsor
13 of 98
Janssen Research & Development, LLC

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 56th largest by enrollment, is one of 10 that started in 2014, is one of 59 in phase 2, and was the 43rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another) castration (any action, surgical, chemical, or otherwise, by which a male loses the functions of the testes) resistant prostate cancer (cancer in prostrate; a gland that makes fluid that aids movement of sperm) (mCRPC), chemo-naive (treatment of cancer is not done using drugs), who received a prior diethylstilbestrol therapy (DES).

Read the detailed description

This is a Phase 2, multinational (when medical research study takes place in more than one country), multicenter (when more than one hospital or medical school team work on a medical research study), open-label (all people know the identity of the intervention), and single arm study to determine benefits of abiraterone acetate and low-dose prednisone to androgen deprivation therapy (ADT) in mCRPC participants who failed to prior DES therapy. The study will consist of a Screening Phase of up to 28 days before enrollment; a PSA Evaluation Phase; and a Follow-up Phase of up to 24 months. Each cycle of abiraterone therapy will be of 28 days. Participants will receive 1000 milligram (mg) abiraterone acetate orally once daily plus prednisone 5 mg orally once daily plus stable regimen of ADT (luteinizing hormone-releasing hormone [LHRH] agonists) as per Investigator's discretion. Treatment will continue until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity. Efficacy will primarily be assessed by time to PSA progression. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Prostatic neoplasms
  • Diethylstilbestrol therapy
  • Abiraterone acetate
  • Prednisone
  • Androgen deprivation therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
  • Prior therapy with diethylstilbestrol (DES) for castration resistant prostate cancer. Participants should demonstrate evidence of progression on DES or evidence of grades 3/4 toxicities on DES
  • disease documented by positive bone scan or metastatic lesions on computerized tomography (CT) or magnetic resonance imaging (MRI)
  • May have received prior androgen blockage (bicalutamide or flutamide) but must have been discontinued for least 28 days
  • Ongoing androgen deprivation therapy (ADT) (luteinizing hormone-releasing hormone [LHRH] agonist or orchiectomy), with serum testosterone level of less than 50 nanogram per deciliter (1.7 nanomole per liter) and eligible participants must maintain ADT

Exclusion criteria

Exclusion Criteria:

  • Active infection or other medical condition that would make prednisone use
  • Any chronic medical condition requiring a higher systemic dose of than 5 milligram (mg) prednisone per day
  • Pathological finding consistent with small cell carcinoma of the prostate
  • Known
  • Has had prior cytotoxic chemotherapy or biologic therapy for the treatment of castration-resistant prostate cancer (mCRPC)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Abiraterone Acetate

    Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.

    Drug: Abiraterone acetate · Drug: Prednisone · Drug: Androgen deprivation therapy (ADT)

Interventions

  • Participants will receive abiraterone acetate 1000 mg (4\*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.

    Also known as: ZYTIGA®, JNJ-212082

  • Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.

  • DrugAndrogen deprivation therapy (ADT)

    Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Time to Prostate-specific Antigen (PSA) Progression

    Time to PSA progression was calculated from date of enrollment to the date of first documentation of PSA progression. As per Prostate Cancer Clinical Trials Working Group (PCWG2) criteria, PSA progression was defined as greater than or equal to (\>=) 25 percent (%) and \>=2 nanogram/milliliter (ng/mL) after 12 weeks (in case of no decline in PSA from Baseline), or first PSA increase that is \>=25% and \>=2 ng/mL above the nadir, and which was confirmed by a second value 3 or more weeks later (in case of decline of PSA from Baseline).

    Time frame: Up to 2 years

Secondary outcomes

  1. Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response

    The PSA response according to Prostate Specific Antigen Working Group 3 criteria was defined as at least 50% decrease in PSA level from Baseline.

    Time frame: Week 12 to any time up to 2 years

  2. Overall Survival

    Overall survival was defined as the time from date of the first dose of abiraterone acetate to the date of death due to any cause. For participants who did not die until the time of analysis, survival time was censored at the time of last contact alive.

    Time frame: Up to 4 years

  3. Percentage of Participants With Pain Progression as Assessed by Brief Pain Inventory - Short Form (BPI-SF) - Pain Severity Score

    The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression was defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.

    Time frame: Up to 2 years

  4. Percentage of Participants With Pain Progression as Assessed by Brief Pain Inventory - Short Form (BPI-SF) - Pain Interference Score

    The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain interference score is mean value for the 7 BPI-SF questions (questions inquiring about the extent of interference with activities by pain) where the extent is ranked from 0 (does not interfere) to 10 (completely interferes). Pain interference progression was defined as an increase in score of 50% or greater from baseline without decrease in analgesic use.

    Time frame: Up to 2 years

  5. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant who will receive study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly.

    Time frame: Up to 4 years

07

Results

Posted Jan 13, 2020

Participant flow

A total of 46 participants were enrolled into the study and were treated with abiraterone acetate and prednisone. Out of 46 participants, 6 did not fulfill all eligibility criteria and included in the safety population. Thirty-five (35) participants completed the study.

Participant flow — Overall Study
MilestoneAbiraterone Acetate
Started46
Completed35
Not completed11
Withdrew: Lost to follow-up2
Withdrew: Death3
Withdrew: Early study termination6

Outcome measures

PrimaryTime to Prostate-specific Antigen (PSA) Progression

Time to PSA progression was calculated from date of enrollment to the date of first documentation of PSA progression. As per Prostate Cancer Clinical Trials Working Group (PCWG2) criteria, PSA progression was defined as greater than or equal to (\>=) 25 percent (%) and \>=2 nanogram/milliliter (ng/mL) after 12 weeks (in case of no decline in PSA from Baseline), or first PSA increase that is \>=25% and \>=2 ng/mL above the nadir, and which was confirmed by a second value 3 or more weeks later (in case of decline of PSA from Baseline).

Time frame:
Up to 2 years
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsAbiraterone Acetate
Time to Prostate-specific Antigen (PSA) Progression7.3 (5.6 to 10.0)
SecondaryPercentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response

The PSA response according to Prostate Specific Antigen Working Group 3 criteria was defined as at least 50% decrease in PSA level from Baseline.

Time frame:
Week 12 to any time up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response
Percentage of participantsAbiraterone Acetate
Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response57.50 (27.0 to 59.1)
SecondaryOverall Survival

Overall survival was defined as the time from date of the first dose of abiraterone acetate to the date of death due to any cause. For participants who did not die until the time of analysis, survival time was censored at the time of last contact alive.

Time frame:
Up to 4 years
Reported as:
Median · Months
Overall Survival
MonthsAbiraterone Acetate
Overall Survival29.6 (16.10 to NA)
SecondaryPercentage of Participants With Pain Progression as Assessed by Brief Pain Inventory - Short Form (BPI-SF) - Pain Severity Score

The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression was defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Progression as Assessed by Brief Pain Inventory - Short Form (BPI-SF) - Pain Severity Score
Percentage of participantsAbiraterone Acetate
Percentage of Participants With Pain Progression as Assessed by Brief Pain Inventory - Short Form (BPI-SF) - Pain Severity Score19.44
SecondaryPercentage of Participants With Pain Progression as Assessed by Brief Pain Inventory - Short Form (BPI-SF) - Pain Interference Score

The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain interference score is mean value for the 7 BPI-SF questions (questions inquiring about the extent of interference with activities by pain) where the extent is ranked from 0 (does not interfere) to 10 (completely interferes). Pain interference progression was defined as an increase in score of 50% or greater from baseline without decrease in analgesic use.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Progression as Assessed by Brief Pain Inventory - Short Form (BPI-SF) - Pain Interference Score
Percentage of participantsAbiraterone Acetate
Percentage of Participants With Pain Progression as Assessed by Brief Pain Inventory - Short Form (BPI-SF) - Pain Interference Score15.15
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant who will receive study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsAbiraterone Acetate
Participants with AEs45
Participants with SAEs11

Adverse events

Collected over Up to 4 years. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone Acetate3/46 (6.5%)11/46 (23.9%)45/46 (97.8%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventAbiraterone Acetate
Cardiac FailureCardiac disorders2/46
PneumoniaInfections and infestations2/46
HaematuriaRenal and urinary disorders2/46
AnaemiaBlood and lymphatic system disorders1/46
Cardio-Respiratory ArrestCardiac disorders1/46
AmaurosisEye disorders1/46
Gastrointestinal ObstructionGastrointestinal disorders1/46
Rectal HaemorrhageGastrointestinal disorders1/46
AstheniaGeneral disorders1/46
CystitisInfections and infestations1/46
Most frequent other events
Showing 10 of 149
Most frequent other events
EventAbiraterone Acetate
Back PainMusculoskeletal and connective tissue disorders21/46
HypertensionVascular disorders19/46
HyperglycaemiaMetabolism and nutrition disorders17/46
FatigueGeneral disorders15/46
AnaemiaBlood and lymphatic system disorders13/46
VomitingGastrointestinal disorders12/46
ArthralgiaMusculoskeletal and connective tissue disorders12/46
Pain in ExtremityMusculoskeletal and connective tissue disorders12/46
NauseaGastrointestinal disorders11/46
Decreased AppetiteMetabolism and nutrition disorders11/46

Baseline characteristics

Age, Continuous
Age, Continuous(years)Abiraterone Acetate
Mean68.8 ± 7.71
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone Acetate
Female0
Male46
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abiraterone Acetate
Asian/Pacific Islander1
Black or African/South American7
Other1
White/Caucasian37
Region of Enrollment
Region of Enrollment(Participants)Abiraterone Acetate
BRAZIL46
08

Study locations

5 sites
  • Porto Alegre, Brazil
  • Rio De Janeiro, Brazil
  • Santo Andre, Brazil
  • Sao Paulo, Brazil
  • São Paulo, Brazil
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Oct 2018, 49 months.

Results were first posted in Jan 2020, 1 year 2 months after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 49 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2014
First posted
Aug 15, 2014
StartActual
Sep 23, 2014
Primary completionActual
Oct 26, 2018
CompletionActual
Oct 26, 2018
Results first posted
Jan 13, 2020
Last update
Jan 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02217566
Responsible party
Sponsor
First posted
Aug 15, 2014
Start date
Sep 23, 2014
Primary completion
Oct 26, 2018
Completion
Oct 26, 2018
Results posted
Jan 13, 2020
Last update
Jan 13, 2020

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion